AbbVie Inc
NYSE: ABBV · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
Updated 2026-04-29
AbbVie Inc (ABBV) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for ABBV.
Valued
Valuation reasonably reflects current fundamentals. Limited margin of safety at these levels.
ABBV historical valuation range
Where current P/E sits in ABBV's own 5Y range.
ABBV intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
ABBV valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
Current: 99.95x
P/S Ratio — History
Current: 5.90x
Is ABBV overvalued in 2026?
AbbVie Inc (ABBV) currently trades at $211.32 per share with a market capitalization of $360,632,943,000.00. Based on our multi-factor framework, the stock trades at a fair valuation with a Smart Value Score of 63/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
The stock trades at a P/E ratio of 100.0x, above its 5-year median of 18.3x. The PEG ratio of 0.48 suggests earnings growth is outpacing the multiple, a classic sign of undervaluation.
Looking at its own history, ABBV is currently trading more expensive than 99% of the last 5Y on P/E. This places it in the 99th percentile of its historical range, a zone where forward returns have typically been muted.
Our discounted cash flow model estimates ABBV's intrinsic value at $163.42 per share, against the current market price of $211.32. This implies a premium to fair value of -29.31%. The current price sits well above what projected cash flows justify, implying investors are paying for growth that has not yet materialized.
The Piotroski F-Score of 5/9 puts financial quality in a middling range, neither a standout strength nor an obvious red flag.
Bottom line: ABBV trades at a fair valuation on our framework, with a Smart Value Score of 63/100. The valuation is defensible but offers no obvious bargain. Patience or a better entry price may reward disciplined buyers.
Frequently asked questions
Is ABBV overvalued in 2026?
Based on a Smart Value Score of 63/100, ABBV is fairly valued. Price reasonably reflects current fundamentals with limited cushion in either direction.
What is ABBV's fair value?
Our DCF model estimates ABBV's intrinsic value at $163.42 per share, versus the current price of $211.32. This produces a margin of safety of -29.31%.
What P/E ratio does ABBV trade at?
ABBV trades at a P/E of 100.0x on trailing twelve-month earnings, compared to its 5-year median of 18.3x.
Is ABBV a buy based on valuation?
WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 63/100 reflects the combined read on growth, quality, and price. The profile is balanced. Best suited for investors with an existing thesis.
How does ABBV's valuation compare to its history?
On P/E, ABBV currently sits in the 99th percentile of its own 5Y range. That is historically expensive relative to where it has traded over the period.
What is ABBV's Smart Value Score?
ABBV's Smart Value Score is 63/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.